Business, Health Care

Bayer and Atara Biotherapeutics enter strategic collaboration for mesothelian-targeted CAR T-cell therapies for solid tumors

Agreement is fundamental element of Bayer’s new Cell & Gene Therapy strategy Bayer to enter CAR T-cell therapy space and expand oncology development pipeline with groundbreaking technology Recognizes the leading position of Atara’s technology platform in allogeneic cell therapy Collaboration will focus

Business, Health Care

Legend Biotech announces Phase 1b/2 study data of cilta-cel, an investigational BCMA CAR-T, showing early, deep, and durable responses in heavily pretreated patients with multiple myeloma

Combined Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 Annual Meeting show 97 percent overall response rate and 12-month progression free survival rate of 77 percent at median follow up of 12.4 months SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”),